Welcome to our dedicated page for Trevena SEC filings (Ticker: TRVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Trevena, Inc. (TRVN) SEC filings page on Stock Titan brings together the company’s regulatory disclosures, allowing investors to review how this CNS-focused biopharmaceutical issuer reports key business developments. Trevena’s filings include annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe its approved product OLINVYK (oliceridine) injection for acute pain in adults, its investigational pipeline candidates TRV045, TRV250 and TRV734, and risk factors related to drug development, commercialization and financing.
Current reports on Form 8-K are particularly important for tracking material events. For example, Trevena has filed 8-Ks describing the determination by the Nasdaq Hearings Panel to delist its common stock from The Nasdaq Stock Market, the subsequent suspension of trading on Nasdaq, and the transition of trading to the OTC markets. Another Form 8-K details an Assignment and Release Agreement under which an R-Bridge-affiliated lender agreed to terminate and release the company from obligations under a royalty-based loan agreement in exchange for Trevena transferring rights under its Chinese License Agreement with Jiangsu Nhwa for royalties in the China territory, other than specified commercialization milestone rights.
Filings also disclose capital structure and financing transactions, such as private placements, warrant exercises and amendments to royalty-based financings related to OLINVYK. These documents outline terms, potential future tranches, and changes in outstanding liabilities, helping readers understand how Trevena funds its operations and manages obligations.
On Stock Titan, Trevena’s SEC filings are updated as new documents are posted to EDGAR. AI-powered tools summarize lengthy reports, highlight sections on OLINVYK safety and labeling, TRV045 development plans, strategic reviews of OLINVYK and pipeline assets, and changes in trading venue or corporate structure. Users can also review disclosures related to royalty arrangements, license agreements and other contracts that shape the company’s financial profile.
Trevena, Inc. entered into an Assignment and Release Agreement under which its lender agreed to terminate and release the company from all obligations under a royalty-based loan agreement, except for indemnification and other obligations that already survive termination under that loan’s existing terms. In return, Trevena agreed to transfer all of its rights, title, and interest in its Chinese License Agreement with Jiangsu Nhwa Pharmaceutical Co. Ltd. for royalties in the China territory. Trevena will retain only the rights to commercialization milestone payments under that Chinese license.
FAQ
What is the current stock price of Trevena (TRVN)?
What is the market cap of Trevena (TRVN)?
